Effectiveness and safety of adjuvant treatment of tislelizumab with or without chemotherapy in patients with high-risk upper tract urothelial carcinoma: a retrospective, real-world study-Reference-Cited by-同舟云学术

Effectiveness and safety of adjuvant treatment of tislelizumab with or without chemotherapy in patients with high-risk upper tract urothelial carcinoma: a retrospective, real-world study

Published:2024-08-22 Issue: Volume: Page:
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Quan Penghe,Zhang Longlong,Yang Bo,Hou Haozhong,Wu Ningli,Fan Xiaozheng,Yu Changjiang,Zhu He,Feng Tianxi,Zhang Yifan,Qu Kejun,Yang Xiaojian^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12094-024-03659-2.pdf

Reference35 articles.

1. Roupret M, Seisen T, Birtle AJ, Capoun O, Comperat EM, Dominguez-Escrig JL, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 Update. Eur Urol. 2023;84:49–64. https://doi.org/10.1016/j.eururo.2023.03.013.

2. Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, et al. Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol. 2011;8:440–7. https://doi.org/10.1038/nrurol.2011.96.

3. Cinque A, Capasso A, Vago R. MicroRNA signatures in the upper urinary tract urothelial carcinoma scenario: ready for the game changer? Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23052602.

4. Kolawa A, D’Souza A, Tulpule V. Overview, diagnosis, and perioperative systemic therapy of upper tract urothelial carcinoma. Cancers (Basel). 2023;15:4813. https://doi.org/10.3390/cancers15194813.

5. Masson-Lecomte A, Vaillant V, Roumiguié M, Lévy S, Pradère B, Peyromaure M, et al. Oncological outcomes of distal ureterectomy for high-risk urothelial carcinoma: a multicenter study by The French Bladder Cancer Committee. Cancers. 2022;14:5452. https://doi.org/10.3390/cancers14215452.